Stockscreener 앱 받기
0.00
100.00%
-41.03
시간 외 거래:
41.06
41.06
+
전일 마감가:
$41.03
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$5.25B
수익:
$1.11B
순이익/손실:
$133.27M
주가수익비율:
0.00
EPS:
1.0006
순현금흐름:
$37.47M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$41.14
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
0.00 | 5.25B | 1.11B | 133.27M | 37.47M | 1.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 개시 | Roth Capital | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2026-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS Suspended by Cantor Fitzgerald -- Rating Remains Neutral - GuruFocus
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals - BioPharm International
Biogen upgraded to Hold after Apellis acquisition boosts prospects despite challenges. - Pluang
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins - TechStock²
Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) - Stock Titan
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - Yahoo Finance
Biogen Completes Acquisition of Apellis Pharmaceuticals - Sahm
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen Acquires Apellis Pharmaceuticals (APLS) to Enhance Growth Potential - GuruFocus
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Biogen–Apellis (APLS) deal triggers GC’s cash, CVR and option changes - Stock Titan
Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders - Stock Titan
Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Biogen (APLS counterparty) closes Apellis tender offer and merger with cash and CVR deal - Stock Titan
Biogen stock (US09062X1037): closes $5.3B Apellis deal - AD HOC NEWS
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over - TechStock²
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):